Evaluation of the effects of peripheral CB1 receptor antagonism on obesity and metabolic dysfunction

Obesity is a growing public health concern that is characterized by increased fat mass. It is also an important risk factor for various diseases, such as type 2 diabetes. Most treatments for obesity act on the brain, and interestingly, none of the available treatments target fat cells, the key cell type involved in the development of obesity. While it is known that blocking the actions of the CB1 receptor can reduce food intake and treat obesity, the effect of CB1 receptor blockade in peripheral fat tissue has not been investigated in great detail. This project is aimed at evaluating the effectiveness of new generation CB1-receptor inverse agonists, that preferentially act in the periphery, in treating obesity. The benefit of this project to Inversago, the partner organization, is to advance preclinical candidate compounds towards clinical use in treating obesity and metabolic disorders.

Faculty Supervisor:

Gareth Lim

Student:

Partner:

Inversago Pharma

Discipline:

Life Sciences

Sector:

Manufacturing

University:

Université de Montréal

Program: